1. Home
  2. DGICB vs FULC Comparison

DGICB vs FULC Comparison

Compare DGICB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICB

Donegal Group Inc. Class B

HOLD

Current Price

$17.69

Market Cap

565.4M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$8.00

Market Cap

462.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICB
FULC
Founded
1986
2015
Country
United States
United States
Employees
851
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
565.4M
462.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
DGICB
FULC
Price
$17.69
$8.00
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
2.0K
1.0M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
3.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.84
$2.32
52 Week High
$20.30
$15.74

Technical Indicators

Market Signals
Indicator
DGICB
FULC
Relative Strength Index (RSI) 56.64 52.75
Support Level $15.57 $6.33
Resistance Level $17.80 $8.17
Average True Range (ATR) 0.57 0.49
MACD 0.21 0.19
Stochastic Oscillator 66.75 95.73

Price Performance

Historical Comparison
DGICB
FULC

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: